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AbstrAct
Objectives The incidence of HIV and syphilis among 
men who have sex with men (MSM) in Europe has 
recently increased. Rapid point-of-care tests (POCTs) for 
syphilis can improve access to screening. The purpose 
of this study was to evaluate the performance of two 
syphilis POCTs compared with laboratory tests among 
MSM.
Methods The study was undertaken in Verona, Italy. 
Asymptomatic MSM, potentially exposed to syphilis, were 
enrolled prospectively. The POCTs evaluated were SD 
Bioline Syphilis 3.0 and Chembio DPP Syphilis Screen & 
Confirm Assay on both serum and fingerprick blood. The 
results of the POCTs were read by the naked eye by two 
independent readers and their concordance assessed.
results A total of 289 MSM were enrolled in the 
study. Based on laboratory tests, 35 MSM (12.1%) 
were TPPA-positive alone and 16 (5.5%) were both 
Treponema pallidum particle agglutination test (TPPA) 
and rapid plasma reagin (RPR)-positive. The specificities 
of both POCTs were above 99% on both serum and 
fingerstick blood specimens, while sensitivities varied 
considerably. The sensitivity of the SD Bioline test 
was lower on fingerprick blood (51.4% and 54.3%, 
readers 1 and 2, respectively) compared with that on 
serum (80.0% and 82.9%). In contrast, the Chembio 
test exhibited similar sensitivity values for serum and 
fingerprick samples (57.7% and 64.0% on serum vs 
65.4% and 69.2% on fingerprick for the treponemal 
component; 63.6% on both samples by both readers 
for the non-treponemal component). The positive 
predictive value ranged between 100% and 93.9% for 
the treponemal component of both syphilis POCTs, but 
was lower (76.3%–100%)%) for the non-treponemal 
component of the Chembio POCT. The negative 
predictive value surpassed 90% for both tests on both 
samples. The agreement between readers was very high 
(>99%).
conclusion The diagnostic performance of the syphilis 
POCTs was lower than expected; however, considering 
the prevalence of syphilis among MSM, POCTs should 
be recommended to improve syphilis detection among 
MSM.
bAckgrOund
WHO strongly recommends screening for HIV and 
syphilis, as well as for other STIs among most at-risk 
populations to reduce the burden of morbidity and 
mortality associated with undiagnosed and thus 
untreated infection.1 2
In Europe and in the European Economic Area, 
the main mode of HIV transmission is unprotected 
sexual intercourse between men. From 2004 to 
2013, the number of new HIV cases among men 
who have sex with men (MSM) increased by 33%, 
and in 2013, 42% of all new cases were in this 
population.3 Furthermore, in this high-risk group, 
the incidence of syphilis has increased every year 
since 2008, and in 2014, 63% of new cases were 
reported among MSM.4
In Italy, available data suggest that in urban 
areas the HIV prevalence rate among MSM is 
approximately 10%.3 According to the find-
ings of the EU-funded Sialon II project, an HIV 
prevalence of 9.6% was estimated among MSM 
in Verona.5 In addition, in the same study an 
overall treponemal seropositivity rate of 12.7% 
was detected and non-treponemal test positivity 
confirmed with a positive treponemal test (a better 
indicator of active disease) was 5.1%.5 These find-
ings are consistent with the prevalence rates of 
HIV and syphilis among MSM reported elsewhere 
in Europe.3
Although HIV transmission can be influenced by 
many factors, the presence of a coexisting syphilis 
infection might lead to increased viral shedding 
through ulcers and an increased viral load as a result 
of the concomitant effect of syphilis on the immune 
system.6 7 Both HIV and syphilis may be asympto-
matic for long periods but, if untreated, could lead 
to continued transmission and severe complica-
tions. This chain of events could be tackled through 
early testing and subsequent treatment. Moreover, 
the introduction of syphilis screening into existing 
HIV testing programmes would be cost-effective, 
time-saving and would have a considerable impact 
on the prevention of transmission, case finding and 
personal health.2
Since 2006, WHO has been actively working to 
promote a more efficient use of existing diagnostic 
tools for STIs, as well as to support a more efficient 
adaptation of such tools to different populations 
and settings. From this perspective, both develop-
ment of and evaluation initiatives for new STI diag-
nostic technologies have been promoted to ensure 
appropriate performance and availability of these 
technologies to improve diagnostic services for 
those populations most at risk.2
Point-of-care tests (POCTs) for syphilis are prom-
ising tools to improve large-scale screening, espe-
cially among hard-to-reach populations, such as 
MSM, in different settings. The availability of test 
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results within 20 min allows for prompt clinical decisions and 
reduces the loss to follow-up.8
Therefore, in recent years, a remarkable number of rapid diag-
nostic tests (RDTs) for syphilis and/or HIV have been developed 
and several national health systems have scaled up their use as 
part of their STI testing policies.9
Recently, the WHO STI POCT initiative published a target 
product profile for syphilis POCTs. According to this profile, 
a syphilis POCT should have a sensitivity of at least 80% and 
a specificity >90%. These standards ensure acceptable positive 
predictive value (PPV) and negative predictive value (NPV) and a 
major effect in terms of clinical utility in low-income, middle-in-
come countries and, by extension, among hard-to-reach popu-
lations, where similar high rates of syphilis prevalence (3%–5%) 
have been reported.10
The diagnostic performance of some POCTs and their easy 
and rapid utility make them, under specific conditions, a prac-
tical alternative to standard laboratory testing methods.11 
Nevertheless, the results obtained with POCTs can be influenced 
by epidemiological/environmental factors. With regards to the 
human component, the impact of the user’s characteristics, such 
as the ability to properly follow the rapid testing procedures 
(capillary blood taking, correct timing of adding the buffer and 
reading), could substantially interfere with the performance of 
the POCT. Performance, therefore, is dependent not only on the 
technical characteristics of the POCT itself, but also of human 
factors that can impact on the correct use and interpretation of 
the POCT.
To our knowledge, the human factor has not yet been compre-
hensively analysed as a key component of the testing procedure. 
While many performance evaluation studies of syphilis POCTs 
have been published, none of them has specifically targeted 
MSM as a target study population. In our study, the predictive 
positive and negative values of the POCTs could be estimated 
not only as a result of testing the sample of men included in 
the study, but also using the seroprevalence data derived from 
an integrated bio-behavioural survey recently carried out among 
the MSM population living in Verona.5
The purpose of this study was to evaluate the analytical and 
diagnostic performance (including human factors) of two syph-
ilis rapid tests compared with laboratory-based gold standard 
tests when applied to an MSM population. In particular, labora-
tory-based treponemal tests were used in comparison with both 
the SD Bioline treponemal test and the treponemal component 
of the Chembio test. The Chembio non-treponemal component 
was compared with a laboratory-based non-treponemal test.
MethOds
study sites and population
Study participants were asymptomatic MSM, potentially 
exposed to syphilis as a result of risky behaviours, prospectively 
recruited from the Sialon II Respondent-Driven Sampling survey 
implemented in Verona, Italy,12 from 2013 to 2014 and MSM 
attending the Infectious Diseases Unit of the Verona University 
Hospital screening facility from 2015 to 2016. The prevalence 
of HIV, TPPA and dually TPPA/RPR seropositivity used for 
the evaluation of the performance of the POCTs was based on 
the results of an integrated bio-behavioural survey carried out 
among the Verona MSM population.5
Men or male-to-female transgenders, ≥18 years, who had 
sex with at least another man over the last 12 months and who 
provided witnessed written informed consent were included in 
the study. Participants could be enrolled in the study only once.
Study participants were given an automatically generated 
unique bar code to participate anonymously and to link partic-
ipants to their own test results. A structured questionnaire was 
used to collect information about demographic and behavioural 
characteristics, whereas a specific form was used to collect data 
about the participant’s syphilis history.
The sample size was calculated at an expected prevalence of 
10%. This sample size yielded 30 subjects with treponemal posi-
tivity, which achieves 85% power to detect a change in sensitivity 
from 0.58 to 0.85 using a two-sided binomial test and a >99% 
power to detect a change in specificity from 0.58 to 0.85 using a 
two-sided binomial test. The target significance level was 0.025 
(Bonferroni correction). The actual significance level achieved 
by the sensitivity was 0.015 and achieved by the specificity was 
0.019.
POcts under evaluation
The tests evaluated in this study were the SD Bioline Syphilis 
3.0 (Standard Diagnostics, South Korea) and the DPP Syphilis 
Screen & Confirm Assay (Chembio Diagnostic Systems, USA).
Both are immunochromatographic assays. SD Bioline Syphilis 
3.0 test is a treponemal assay, which detects antibodies of all 
isotypes (IgG, IgM, IgA) against Treponema pallidum. Chembio’s 
DPP Syphilis Screen & Confirm Assay can simultaneously detect 
antibodies against treponemal and non-treponemal antigens.
Chembio RDT employs a unique combination of protein A 
and anti-human IgM antibody, which are conjugated to colloidal 
gold particles for the treponemal test. It uses a recombinant 
antigen of T pallidum and synthetic antigens for the non-tre-
ponemal test, separately bound to the membrane’s solid phase.13
In both tests, the presence of the treponemal and, when avail-
able, non-treponemal magenta-coloured lines was evaluated 
independently by the naked eye by two readers who were blind 
to each other’s results and to the clinical history of the study 
participants.
The POCTs under evaluation were partially donated by the 
manufacturers or purchased with external funding, namely from 
the 2008–2013 EU Public Health Programme, through which 
the Sialon II Respondent-Driven Sampling survey component 
has been funded. The manufacturers were not involved in any 
part of the study (study design, data collection, data analysis, 
data interpretation and writing of the paper).
reference laboratory tests
These results were compared with those of the syphilis serolog-
ical laboratory standard assays. For the treponemal component, 
two treponemal tests were used: the chemioluminescent assay 
(CLIA) (ADVIA Centaur Syphilis assay, Siemens Healthcare, 
Germany) and TPPA (SERODIA-TP·PA, Fujirebio Diagnostics, 
Sweden). For the non-treponemal component, RPR (Syphilis 
RPR test, HUMAN Diagnostics Worldwide, Germany) was used 
as reference test. According to the standard laboratory proce-
dure, the titration for TPPA and RPR was also recorded.
specimen collection, testing procedures and POcts results 
reading
According to the international and local standard guidelines, 
pre-test and post-test counselling was provided to all participants.
The testing procedures, based on the manufacturers’ instruc-
tions for fingerprick whole blood, venepuncture whole blood 
and serum specimens, were strictly followed.
The required amount of capillary (manufacturers’ pipettes) 
and venous blood (5 mL) was collected by trained healthcare staff 
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of the Verona University Hospital. With reference to obtaining 
fingerprick blood samples, the manufacturers’ instructions 
were followed step-by-step, such as wiping away the first drop 
of blood following pricking, collecting the required amount of 
capillary blood using the capillary pipette provided in both test 
kits and waiting 20 min (measured with a timer for each test) 
before reading the results.
In addition, a double reader method [Reader 1-Reader 2, 
(R1–R2)] was adopted. The readers were medical doctors and 
nurses in the clinical setting and lab technicians in the laboratory 
setting. All readers were specifically trained as described in the 
‘Training and materials’ section.
According to the procedure, (i) R1–R2 assessed the RDT 
results blindly from one to another using two separate forms 
for recording the assigned result, (ii) neither R1 nor R2 was 
informed about the clinical history of the patient and (iii) R1 
and R2 changed according to the setting (lab/clinical setting). 
Because of the potential reading bias due to his/her knowledge 
of the patients’ syphilis history, the counsellor involved in the 
pre-test/post-test counselling was always excluded from the 
result assessment of the counselled participant.
In the clinical setting, syphilis POCTs performed on fingerstick 
blood were read immediately. Blood tubes were sent, according 
to routine procedures, to the Microbiology Unit of the Verona 
University Hospital where they were centrifuged to obtain serum 
and to perform the laboratory-based syphilis serological tests. 
The specimens that could not be processed immediately were 
stored at 4°C and processed within 3–4 days to allow respond-
ents to receive their syphilis serological results, using the bar 
code provided at enrolment. The evaluation of POCTs’ perfor-
mance on serum at the Microbiology laboratory was carried out 
on batches of previously stored (−80°C) serum samples.
During the post-test counselling, in the case of a positive 
result of serological test for T pallidum infection (syphilis), treat-
ment was made available to participants according to the local 
protocol.
training and materials
In order to ensure a proper implementation of the research 
protocol and to standardise the human component in performing 
the POCTs, the following actions were carried out: (i) specific 
on-site prevalidation training of health professionals was under-
taken for the reading procedures; (ii) the use of specific training 
materials (including picture examples of different bars of the 
RDTs to train readers to ensure correct reading); (iii) a coaching 
programme to ensure proper monitoring of the validation exer-
cise and (iv) the use of a specific set of standardised materials 
for the readers (eg, posters summarising the POCT procedures 
displayed in the blood taking settings, a table mat summarising 
the procedures nurses had to follow when performing the 
POCTs, posters outlining the reading procedures of the testing 
always visible in the reading rooms for R1–R2, clarifying the 
different interpretations of the tests’ results).
ethics
Research protocols were submitted to and approved by the 
local Ethics Committee (Comitato Etico per la Sperimentazione 
Clinica delle province di Verona e Rovigo). Protocols were also 
approved by both the WHO Research Project Review Panel 
(RP2) and the WHO Research Ethics Review Committee (ERC) 
before initiating data collection.
Anonymity and confidentiality of respondents’ data were 
guaranteed in line with the local standards, while a bar code 
system has been instituted to allow an appropriate link between 
the different types of data collected for each individual (demo-
graphic and behavioural information, biological samples).
In particular, to comply with all ethical and legal aspects and 
to minimise the risk of mistakes, participants were informed 
both during the pre-counselling session and through the 
informed consent form that only the results of laboratory-based 
tests would be used to direct patient management. These labora-
tory results were made available to each participant within a few 
days of enrolment. Participants were also provided with a phone 
number to be used (i) to know whether the lab results were avail-
able and (ii) to book an appointment for collection of results.
In addition, in cases of positive results, MSM received further 
information about the infection and the treatment during post-
test counselling. According to local procedures, participants 
could decide to attend the Infectious Diseases Unit of the Verona 
University Hospital for clinical follow-up or another centre of 
care. In each case, prompt referral was guaranteed. The treat-
ment provided was in line with national guidelines and standards.
Finally, in line with the protocol, samples were stored at 
−80°C at the Microbiology Unit of the Verona University 
Hospital for 1 year after the end of the study. Samples taken 
without written informed consent were not used for testing and 
destroyed immediately.
statistical analysis
Sensitivity, specificity, PPV and NPV for each rapid test were 
estimated comparing the POCT results with the gold standard 
lab tests results.14 The result of each rapid test was compared 
with the respective gold standard, namely POCT treponemal 
versus laboratory-based treponemal and POCT non-treponemal 
versus laboratory-based non-treponemal tests. 95% CIs were 
also estimated (logit transform).
The concordance between R1–R2 readings was estimated by 
calculating percentage agreement (concordance) and Cohen’s κ 
(κ for binary variables).15
Cohen’s κ represents a measure of inter-rater agreement, 
ranging from −1 to +1, where 0 is the level of agreement that 
can be expected in case of random chance. According to the liter-
ature, thresholds for κ are usually categorised as follows: <0.0 
(poor agreement), 0.0–0.2 (slight), >0.2–0.4 (fair), >0.4–0.6 
(moderate), >0.6–0.8 (substantial) and >0.8–1.0 (almost perfect 
agreement).16
STATA V.14.2 was used for all analyses.
results
study population
A sample of 289 MSM was enrolled in the evaluation study. The 
mean age of the participants was 31.4 (median: 29; SD 9.2; min 
18, max 65). Among the overall sample, 20 individuals reported 
a previous syphilis diagnosis before study enrolment (6.8%, 
IC95% 4.4–10.5). All participants provided bio-behavioural 
information, fingerstick whole blood for syphilis rapid testing, 
venous whole blood for HIV and syphilis serological testing.
results of laboratory-based testing
Based on CLIA (ADVIA Centaur Syphilis assay) and TPPA 
(SERODIA-TP·PA) testing, 35 samples were found to be positive 
on treponemal testing (12.1%, 95% CI 8.8 to 16.4), while 16 
samples were found to be reactive on RPR testing (5.5%, 95% 
CI 3.4 to 8.8). All RPR (Syphilis RPR test, HUMAN Diagnos-
tics Worldwide)-positive samples were also TPPA positive. No 
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discordance between the results of the two laboratory trepo-
nemal tests was found.
Performance of the POcts
In line with the availability of the two POCTs, the following 
testing was performed: 289 (100%) SD Bioline Syphilis 3.0 and 
227 (78,5%) Chembio DPP Syphilis Screen & Confirm Assay 
on fingerprick whole blood, 287 (99.3%) SD Bioline and 205 
(70.9%) Chembio DPP on serum.
POCTs sensitivity and specificity, as well as PPV and NPV, 
compared with the golden standard laboratory tests, varied 
considerably according to the tests and biological samples (see 
table 1).
The SD Bioline treponemal test carried out on serum yielded 
a sensitivity of 80.0% for reader 1 (R1) and 82.9% for reader 
2 (R2). With regards to specificity, the performance was 100% 
for R1 and 99.6% for R2. The PPV of the Bioline test was 100% 
for R1 and 96.8% for R2, while the NPVs were 97.2% and 
97.6%, respectively.
When considering the performance of the Bioline test on 
fingerstick blood, the sensitivities were 51.4% and 54.3% for 
R1 and R2, respectively, while specificity was 100.0% for both 
readers. The test showed high values for PPV (100% for both 
readers) and NPV (93.4% and 93.8%).
With regards to the Chembio DPP treponemal POCT on 
serum, the sensitivity values were 57.7% and 64.0% for R1 and 
R2, respectively, while the specificity values were 99.5% and 
99.4. The PPVs (93.9% and 94.4% for R1 and R2) and NPVs 
(94.2% and 95%) were also acceptable.
On whole blood (fingerprick), the sensitivities of the Chembio 
DPP treponemal POCT were 65.4% and 69.2%, for R1 and R2, 
respectively, and a specificity of 99.5% was calculated for both 
readers. PPVs of 95.1% and 95.2% and NPVs of 95.2% were 
calculated for R1 and 95.7% for R2.
For the non-treponemal component of the Chembio test on 
serum samples, a sensitivity of 63.6% was recorded for both R1 
and R2 and specificities of 99.5% for R1 and 99.0% for R2. PPV 
estimates were 86.8% for R1 and 76.3% for R2, while the NPV 
was 98.1% for both readers.
The results on fingerstick samples (whole blood) showed 
a sensitivity of 63.6% for both R1 and R2 and specificities of 
100.0% and 99.5%, respectively. The PPVs were 100% and 
87.9%, while an NPV of 98.1% was calculated for both readers.
rPr and tPPA titration values
In table 2, only positive treponemal reference test has been 
presented and compared with their respective POCT results. 
In part A of the same table, TPPA and RPR-positive cases are 
shown, while in part B, TPPA- positive and RPR-negative cases 
are listed. Considering only part A, among the 289 MSM 
recruited in this study, 16 cases were identified as TPPA+/RPR+ 
(prevalence: 5.5%; 95% CI  3.4 to 8.8). Of these 16 individuals, 
4 were also HIV-seropositive. The clinical evaluation provided 
additional information on the status of the study participants’ 
T pallidum infections. Six individuals had a syphilis history and 
treatment, whereas the remaining 10 subjects had not previ-
ously been diagnosed with a T pallidum infection. The four 
HIV-positive individuals were among those who did not have 
a syphilis history and treatment. In all 16 cases, both the POC 
treponemal tests (SD Bioline and Chembio treponemal compo-
nent) yielded a positive result on serum (100%). As far as the 
Chembio non-treponemal component is concerned, among the 
TPPA+/RPR+ cases, the test was carried out only on 10 individ-
uals out of 16. In this subsample, three cases would have been 
missed if only the POCT had been used, considering a RPR titre 
≤1:4. One of the cases missed by the test was among the indi-
viduals with a syphilis history (possible serofast state), while the 
other two cases had not been diagnosed previously.
When whole blood specimens were analysed, SD Bioline 
missed one of the TPPA+/RPR+ cases (TPPA 1:5120, RPR 1:2 
and no syphilis history and treatment), while the treponemal 
component of the Chembio test did not miss any cases (although 
carried out on only 10 out of 16 participants), while its non-tre-
ponemal component missed three cases. The very same cases 
missed on fingerprick blood specimens were also those missed 
when serum specimens were tested.
Part B of table 2 shows that the higher the TPPA titre, the 
better the performance of the POCTs’ treponemal component. 
This is particularly evident when performance was assessed on 
fingerprick blood specimens.
r1–r2 concordance (cohen’s κ) and agreement on rdts 
result assessment
Table 3 shows a very high agreement between R1 and R2 for 
both POCTs through both concordance percentages and Cohen’s 
κ, the latter ranging from 0.91 to 0.97.16 With regards to the SD 
Bioline POCT, κ showed an almost perfect agreement between 
table 1 Point-of-care test sensitivity and specificity, positive predictive value (PPV) and negative predictive value (NPV), per specimen (estimated 
syphilis prevalence: 12.7%; estimated active syphilis prevalence: 5.1%), according to the assessment of the readers (R1, R2), compared with the lab-
based golden standard (TPPA for the treponemal component, RPR for the non-treponemal component)
sensitivity (%) 95% cI specificity (%) 95% cI PPV (%) 95% cI nPV (%) 95% cI
Serum Bioline TREP R1 80.0 63.1 to 91.6 100.0 98.6 to 100.0 100.0 78.5 to 99.9 97.2 94.6 to 98.4
R2 82.9 66.4 to 93.4 99.6 97.8 to 100.0 96.8 81.0 to 99.5 97.6 95.1 to 98.8
Chembio TREP R1 57.7 36.9 to 76.6 99.5 97.0 to 100.0 93.9 68.0 to 99.1 94.2 91.2 to 96.2
R2 64.0 42.5 to 82.0 99.4 96.9 to 100.0 94.4 69.9 to 99.2 95.0 91.8 to 97.0
Non-TREP R1 63.6 30.8 to 89.1 99.5 97.2 to 100.0 86.8 46.9 to 98.0 98.1 96.0 to 99.1
R2 63.6 30.8 to 89.1 99.0 96.3 to 99.9 76.3 43.0 to 93.2 98.1 95.9 to 99.1
Blood Bioline TREP R1 51.4 34.0 to 68.6 100.0 98.6 to 100.0 100.0 70.1 to 99.8 93.4 91.0 to 95.2
R2 54.3 36.6 to 71.2 100.0 98.6 to 100.0 100.0 71.3 to 99.8 93.8 91.3 to 95.5
Chembio TREP R1 65.4 44.3 to 82.8 99.5 97.3 to 100.0 95.1 72.8 to 99.3 95.2 92.1 to 97.1
R2 69.2 48.2 to 85.7 99.5 97.2 to 100.0 95.2 73.6 to 99.3 95.7 92.6 to 97.5
Non-TREP R1 63.6 30.8 to 89.1 100.0 98.3 to 100.0 100.0 46.6 to 99.6 98.1 96.1 to 99.1
R2 63.6 30.8 to 89.1% 99.5 97.4 to 100.0 87.9 49.3 to 98.2 98.1 96.0 to 99.1
R1, reader 1; R2, reader 2.
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R1 and R2 on both serum samples (κ=0.96) and blood samples 
(κ=0.91), as well as a high percentage of agreement value 
(99.30% and 98.96%).
For the treponemal component of Chembio DPP, κ value was 
0.97 for both serum and blood, and an agreement of 99.51% 
(serum) and 99.56% (blood) was reported. With regards to the 
non-treponemal tests, κ values were 0.94 and 0.93 and an agree-
ment of 99.50% and 99.56% was estimated.
dIscussIOn
The use of POC tests is becoming increasingly frequent world-
wide in clinical and low threshold testing settings.
The use of syphilis rapid tests has been extensively reported 
in the literature among different types of populations, particu-
larly among vulnerable populations (eg, pregnant women, sex 
workers, injecting drug users (IDUs)); however, to our knowl-
edge, MSM have been less studied. Considering surveillance 
data on syphilis among MSM, the use of syphilis POC rapid 
tests can potentially represent an important clinical and public 
health measure to diagnose syphilis cases among hard-to-reach 
segments of this target population. In this study, a homogeneous 
sample was enrolled. All participants were MSM living in the 
same city and very likely belonging to the same community. 
In addition, the prevalence of TPPA+ and TPPA+/RPR+ for 
calculating PPV and NPV was based on a large bio-behavioural 
survey carried out among MSM in Verona in 2013–2014,5 12 and 
therefore, with this more robust prevalence estimate, providing 
a more valid indication of the real-life POCTs utility among this 
population. However, the small sample used for this validation 
study probably represents the most important limitation in terms 
of result generalisability and performance assessment; therefore, 
the results of this study should be cautiously interpreted.
Aware of this limitation, the study team used several meth-
odological and operational features to assure appropriate data 
collection and proper interpretation of the results. The real-life 
clinical implementation of this study, with the use of fingerprick 
blood in the clinical setting and serum in the laboratory, provided 
a good opportunity to assess the diagnostic performance of the 
two syphilis rapid tests. The performance on both biospeci-
mens resulted in lower-than-expected performance characteris-
tics compared with previous reports in the literature and in the 
technical specifications provided by the manufacturers. This is 
particularly evident when fingerprick blood samples were tested. 
In addition, considering the titration provided by the laboratory 
tests, it seems that for TPPA titres >1:1280 the misclassification 
rate for the two POCTs, both on serum and blood, was extremely 
low. The same pattern can be seen for the non-treponemal test, 
where with RPR titres ≥1:8 there was virtually no misclassifi-
cation compared with the non-treponemal component of the 
Chembio test. As suggested by some studies in prenatal popula-
tions, the detection of RPR titres≥1:8 could be very important 
for pregnant women as this has been significantly associated with 
adverse pregnancy outcomes.17 Unfortunately, for other at-risk 
populations, the use of a decision threshold titre is more prob-
lematic owing to possible recent exposure to infection and there-
fore incubation of early disease. The interpretation of low RPR 
titres can be even more difficult when patients have previously 
received treatment with a course of potentially treponemocidal 
antibiotics for other indications. In fact, 16%–20% of men with 
a history of adequately treated syphilis can present lifelong low 
positive RPR titres (ie, they are serofast).18
Based on their STI history, participants with a treponemal-pos-
itive result were classified as either a newly diagnosed or a sero-
fast case. The non-treponemal Chembio test missed three TPPA+/
RPR+ cases; however in terms of clinical utility, at least one case 
was serofast and therefore negligible in terms of transmission risk 
and individual health outcome, while the remaining two were 
possibly cases of late-latent disease. In these latter cases, the clinical 
implication for the missed treatment could have been relevant for 
the patient, but not for the community since the transmission risk of 
a late-latent syphilis is extremely low.19 It is interesting to note that 
there was no discordance in these cases when serum and blood test 
results were compared and that none of the MSM who could be 
considered serofast was HIV- infected.
Unfortunately, due to unexpected logistical reasons (expi-
ration time and delay in new test procurement), the Chembio 
POCT results were available only for a subsample of MSM 
and this represented a further limitation in the interpretation 
of our findings. However, the TPPA titre and RPR comparisons 
seem to be in line with the results of previous studies.20–22 Addi-
tional evaluation studies should be implemented, including a 
more detailed assessment on the potential impact of different 
cut-off (TPPA and RPR titre) on the Chembio DPP Syphilis 
Screen & Confirm Assay performance, within a POCT approach.
Sensitivity and specificity varied considerably across tests and 
biospecimens, as well as PPV and NPV. While the analytical 
performance of RDTs (sensitivity and specificity) is not affected 
by the characteristics of the population among which the tests 
are used, PPV and NPV are strongly influenced by the preva-
lence of the infection in the target population. In our study, the 
predictive values seem to be acceptable considering the specific 
evaluation setting and the reference population (members of the 
MSM community in Verona). This leads us to consider the use 
of syphilis POCT as potential alternative to standard methods to 
improve screening practice, particularly outside hospital settings. 
Additional evaluations are certainly needed to further assess the 
potential replacement of standard tests with the POCT approach 
in different scenarios and the potential impact of such a shift.
As expected the performance of the two POCTs evaluated here 
proved to be inferior to those of the standard laboratory tests; 
however, when used strategically, in settings where venepunc-
ture is not safe or impossible to perform, or when the population 
is very mobile or for legal reasons not entitled to receive the 
standard medical assistance (ie, migrants, illegal migrants, sex 
table 3 Agreement between reader 1 and reader 2: agreement and Cohen’s κ values (per type of specimen)
Agreement (%) expected (%) κ  95% cI Z Prob>Z
Serum Bioline TREP 99.30 81.77 0.96 0.91 to 1.00 16.27 0.00
Chembio TREP 99.51 85.06 0.97 0.90 to 1.00 13.79 0.00
Non-TREP 99.50 91.94 0.94 0.82 to 1.00 13.37 0.00
Blood Bioline TREP 98.96 88.02 0.91 0.82 to 1.00 15.53 0.00
Chembio TREP 99.56 84.91 0.97 0.91 to 1.00 14.56 0.00
Non-TREP 99.56 93.58 0.93 0.80 to 1.00 14.03 0.00
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workers, drug users), these POCTs can be extremely useful in 
identifying syphilis cases requiring medical assistance and treat-
ment. Furthermore, even though both syphilis POCTs under 
evaluation seem to be promising, the Chembio POCT seems 
to be more informative, particularly on fingerprick blood. In a 
population with such a high prevalence of TPPA positivity, the 
availability of a rapid syphilis test with a non-treponemal compo-
nent could be very useful as it allows clinicians to better distin-
guish between previously treated syphilis and active disease.
This does not imply that a POCT with only a treponemal 
component is not useful. The treponemal-only test, together 
with the patient’s clinical examination and history, would allow 
the clinician to identify cases never treated, to plan additional 
testing in subjects potentially non-adequately treated or, in case 
of a previous syphilis infection, to treat them despite the margin-
ally hazardous overtreatment risk. The overtreatment risk can be 
balanced with the benefits of the transmission risk reduction to 
partners and the breaking of the transmission chain within the 
community. At a personal level, even though the subject has to be 
treated with penicillin, adverse events associated with treatment 
are fortunately limited.
The procedures adopted for this syphilis test validation addressed 
also the aspect of quality assurance of the test reading in order to 
guarantee an adequate assessment of the POCTs performance. In 
accordance with the literature,23 for reducing the degree of human 
interpretation and subjectivity, an ad hoc training and supporting 
documentations for staff, as well as a coaching activity were devel-
oped. This can be considered a relevant feature of this POCT study 
compared with other studies, where the human component was not 
specifically accounted for or simply considered a negligible factor. 
According to our results, once the POCT procedures (as described 
in the ‘Methods’ section) are strictly followed, the human compo-
nent does not represent a relevant source of inaccuracy. This is 
confirmed by the high level of concordance between the readers 
(Cohen’s κ for R1–R2).
To conclude, we believe that this study could be relevant 
for setting the agenda of future validation studies. Steps and 
procedures for the future use of POCTs in clinical and commu-
nity-based testing services have been piloted, assessed and 
improved for clinical purposes.
From a methodological perspective, despite the fact that POCTs 
are easy to use, this technology should be linked to specific training 
for users together with the use of supporting documentation (eg, 
posters, procedural dashboard) to reduce misinterpretation of 
the results due to human subjectivity. From a clinical viewpoint, 
we can consider the human component as having no significant 
impact on the performance of the POCTs if the healthcare staff is 
properly trained on POCT use. The complex experimental proce-
dures used for this validation study have not fully allowed the staff 
to appreciate the flexibility of POCTs in meeting the diversity of 
medical needs that can make these tools invaluable for this popu-
lation. The possibility of performing the tests in a variety of loca-
tions, including saunas, bathhouses and other non-conventional 
facilities, makes the POCTs very attractive and useful for certain 
healthcare systems. Despite the relatively low sensitivity showed 
by the POCTs in this study, in our opinion they can provide impor-
tant diagnostic and treatment opportunities among the MSM 
population studied. In fact, considering the high specificity (close 
to 100%) the provision of immediate on-site treatment, guided by 
a clinical and epidemiological evaluation (syphilis history, previous 
treatment, exposure assessment), could represent a real benefit 
both for the individuals and for the community as a whole, with a 
consequent reduction of infection transmission and overall burden 
of disease.
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